CM
ROIV icon

Caption Management’s Roivant Sciences ROIV Stock Holding History

Caption Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
+30,000
New +$887K ﹤0.01% 1119
2024
Q4 		– Sell
-157,600
Closed -$1.82M – 1785
2024
Q3 		$1.82M Buy
+157,600
New +$1.79M 0.03% 596

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Caption Management's ROIV Position: Q2 2026 in Review

Caption Management reduced its Roivant Sciences (ROIV) stake by 50% in Q2 2026, selling an estimated $3.24M and leaving 110,000 shares worth $3.89M. The position accounts for 0.02% of the portfolio, ranked #661.

Caption Management first reported a position in ROIV in Q3 2023 and has held it in 9 quarters since. The position peaked at $6.09M in Q1 2026. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Caption Management held 110,000 shares of Roivant Sciences worth $3.89M as of Q2 2026.
  • Caption Management sold 109,800 Roivant Sciences shares in Q2 2026, an estimated $3.24M.
  • Roivant Sciences made up 0.02% of Caption Management's portfolio in Q2 2026, its #661 holding.
  • Caption Management first reported a position in Roivant Sciences in Q3 2023 and has held it in 9 quarters since.
  • Caption Management's Roivant Sciences position peaked at $6.09M in Q1 2026.
  • 499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.